Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.64 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.64 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220223 | 0.84 | QPCT (0.65) | QPCTQPCTLCYP17A1SRCLCK | |
| SCHEMBL3225502 | 0.78 | QPCT (1.00) | QPCTQPCTLCYP17A1SRCHDAC2 | |
| SCHEMBL3206162 | 0.78 | QPCT (0.68) | QPCTQPCTLCYP17A1SRC | |
| SCHEMBL3218135 | 0.78 | QPCT (0.72) | QPCTQPCTLSRCTDO2ALDH1A3 | |
| SCHEMBL3260750 | 0.74 | QPCT (0.67) | QPCTQPCTLCYP17A1SRCTBXAS1 | |
| SCHEMBL3217600 | 0.74 | QPCT (0.62) | QPCTQPCTLCYP17A1LCKIDO1 | |
| SCHEMBL31280538 | 0.72 | QPCT (0.45) | QPCTQPCTLCYP17A1SRCTBXAS1 | |
| SCHEMBL4550275 | 0.71 | SRC (0.51) | QPCTQPCTLCYP17A1SRCTBXAS1 | |
| SCHEMBL12698760 | 0.71 | QPCT (0.68) | QPCTQPCTLCYP17A1TBXAS1IDO1 | |
| SCHEMBL12698953 | 0.71 | QPCT (0.55) | QPCTQPCTLCYP17A1SRCTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | claimed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | claimed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | claimed |
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| EP-2118101-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234313-A1 | NOVEL INHIBITORS | SF3A1, HBS1L, SF3A3 | QPCT 4475/4885QPCTL 4381/4885CYP17A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.